Marengo's precision, Vβ chain targeted T cell activator technology reinvigorates anti-tumor immune responses in refractory tumor models Invikafusp alfa is being evaluated as a single-agent in an ongoing Phase 1/2 clinical trial (STARt-001) to treat PD(L)1 resistant "cold" cancers First disclosure of preliminary Phase 1 clinical results from the STARt-001 study CAMBRIDGE, Mass. , Oct. 30, 2024 /PRNewswire/ -- Marengo Therapeutics, Inc.
, a clinical-stage biotechnology company pioneering novel approaches to precision T cell activation, today announced first-in-human clinical data for its lead selective T cell activator, invikafusp alfa (STAR0602), will be presented in a late-breaking oral presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting taking place November 8-10 th , 2024 in Houston, Texas . Presentation details: Title: A Phase 1/2 study of Invikafusp alfa (STAR0602), a first-in-class TCR β chain-targeted bispecific antibody, as monotherapy in patients with antigen-rich solid tumors resistant to anti-PD(L)1 Conference: 39th SITC Annual Meeting Abstract Number: LBA-1470 Session Title: Late-Breaking Abstract Session 2 Session Date and Time: Saturday, November 9, 2024 , 11:45 AM - 12:15 PM Presenter: James L. Gulley , M.
D., Ph.D.
(National Cancer Institute, Bethesda, Maryland , USA) About Marengo Therapeutics Marengo Therapeutics, Inc. is a clinical-stage biotechnology company advancing innovative T cell-targeting therapies to revolutionize ca.
